Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.
作者信息
Whiteside T L
机构信息
University of Pittsburgh Cancer Institute and Department of Pathology, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA.
出版信息
Clin Diagn Lab Immunol. 2000 May;7(3):327-32. doi: 10.1128/CDLI.7.3.327-332.2000.
Abstract
摘要
相似文献
1
Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.对接受免疫治疗的癌症患者的抗原特异性细胞毒性T淋巴细胞的监测。
Clin Diagn Lab Immunol. 2000 May;7(3):327-32. doi: 10.1128/CDLI.7.3.327-332.2000.
2
Degeneracy instead of specificity: is this a solution to cancer immunotherapy?简并性而非特异性：这是癌症免疫疗法的一种解决方案吗？
Trends Immunol. 2002 Jul;23(7):343-4; author reply 344-5. doi: 10.1016/s1471-4906(02)02250-0.
3
Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy.具有抗原特异性受体的T细胞的生死抉择——利用T细胞进行癌症过继性免疫治疗/基因治疗
Curr Gene Ther. 2001 Sep;1(3):253-5. doi: 10.2174/1566523013348607.
4
Relevance of the T cell receptor for immunotherapy of cancer.T细胞受体在癌症免疫治疗中的相关性。
Cancer Immunol Immunother. 1994 Jul;39(1):1-14. doi: 10.1007/BF01517174.
5
Immunotherapy II: Antigens, receptors and costimulation.免疫疗法II：抗原、受体与共刺激
Cancer Metastasis Rev. 1996 Sep;15(3):329-49. doi: 10.1007/BF00046346.
6
T cell receptors and cancer: gain gives pain.T细胞受体与癌症：得亦痛
Nat Med. 2010 May;16(5):520-1. doi: 10.1038/nm0510-520.
7
Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.基于过继性细胞疗法和免疫检查点阻断疗法的实体瘤个性化联合免疫疗法的前景。
Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68.
8
Adoptive T cell therapy: Boosting the immune system to fight cancer.过继性 T 细胞疗法：增强免疫系统以对抗癌症。
Semin Immunol. 2020 Jun;49:101437. doi: 10.1016/j.smim.2020.101437. Epub 2020 Nov 29.
9
[T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases].[具有修饰特异性的T淋巴细胞在恶性疾病治疗中的应用]
Mol Biol (Mosk). 2017 Nov-Dec;51(6):1008-1023. doi: 10.7868/S002689841706012X.
10
Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination?细胞毒性T淋巴细胞识别的人类肿瘤抗原：用于疫苗接种？
Stem Cells. 1995 Jul;13(4):393-403. doi: 10.1002/stem.5530130410.
引用本文的文献
1
adhesin protein-conjugated thermal responsive hybrid nanoparticles for photothermal and immunotherapy against cancer and its metastasis.黏附蛋白偶联热响应性杂化纳米粒子用于光热和免疫治疗癌症及其转移。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002666.
2
Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.基于 HLA-Ig 的“乐高式系统”用于 T 细胞监测、调节和扩增的概述。
Immunol Res. 2010 Jul;47(1-3):248-56. doi: 10.1007/s12026-009-8156-z.
3
Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.采用γ干扰素酶联免疫斑点试验评估人类免疫缺陷病毒特异性T细胞定量检测的实验室间一致性。
Clin Vaccine Immunol. 2006 Jun;13(6):684-97. doi: 10.1128/CVI.00387-05.
4
Development and use of multimeric major histocompatibility complex molecules.多聚体主要组织相容性复合体分子的开发与应用。
Clin Diagn Lab Immunol. 2002 Mar;9(2):216-20. doi: 10.1128/cdli.9.2.216-220.2002.
本文引用的文献
1
Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.抗原特异性T淋巴细胞的表型分析。《科学》。1996年。第274卷：94 - 96页。
J Immunol. 2011 Jul 1;187(1):7-9.
2
Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.对接受抗肿瘤疫苗的癌症患者中γ干扰素产生情况的改良酶联免疫斑点测定法的评估。
Clin Diagn Lab Immunol. 2000 Mar;7(2):145-54. doi: 10.1128/CDLI.7.2.145-154.2000.
3
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.黑色素瘤抗原A/MART-1（51-73）代表一种免疫原性的、受HLA-DR4限制的表位，可被黑色素瘤反应性CD4(+) T细胞识别。
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5. doi: 10.1073/pnas.97.1.400.
4
Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.鉴定人血中 CD4(+) 或 CD8(+) T 淋巴细胞识别的经自然加工且由 HLA 呈递的爱泼斯坦-巴尔病毒肽段。
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12033-8. doi: 10.1073/pnas.96.21.12033.
5
Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent.细胞毒性T淋巴细胞（CTL）与肽-主要组织相容性复合体I类四聚体复合物相互作用的特异性取决于温度。
J Immunol. 1999 Oct 15;163(8):4342-8.
6
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.在很大比例的人类组织相容性白细胞抗原（HLA）-A2个体中，幼稚型黑色素瘤抗原A/MART-1特异性CD8(+) T细胞的频率很高。
J Exp Med. 1999 Sep 6;190(5):705-15. doi: 10.1084/jem.190.5.705.
7
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.黑色素瘤患者中肿瘤相关抗原特异性循环T细胞的特征分析。
Nat Med. 1999 Jun;5(6):677-85. doi: 10.1038/9525.
8
Soluble, high-affinity dimers of T-cell receptors and class II major histocompatibility complexes: biochemical probes for analysis and modulation of immune responses.T细胞受体与II类主要组织相容性复合体的可溶性高亲和力二聚体：用于分析和调节免疫反应的生化探针。
Cell Immunol. 1999 Mar 15;192(2):175-84. doi: 10.1006/cimm.1999.1441.
9
A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients.一种用于检测健康供体和黑色素瘤患者血液中针对源自流感蛋白的HLA I类结合肽表位特异性CD8 + T淋巴细胞的灵敏ELISPOT检测法。
Clin Cancer Res. 1997 Feb;3(2):221-6.
10
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.黑色素瘤肽疫苗免疫患者：使用ELISPOT检测法进行免疫评估。
Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23.
Zotero 插件